Production (Stage)
Castle Biosciences, Inc.
CSTL
$16.10
$0.211.32%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 87.99M | 86.31M | 85.78M | 87.00M | 72.97M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 87.99M | 86.31M | 85.78M | 87.00M | 72.97M |
| Cost of Revenue | 16.38M | 16.18M | 15.61M | 14.52M | 13.89M |
| Gross Profit | 71.61M | 70.13M | 70.17M | 72.48M | 59.08M |
| SG&A Expenses | 58.62M | 49.97M | 50.50M | 51.09M | 48.50M |
| Depreciation & Amortization | 28.33M | 4.34M | 2.27M | 2.25M | 2.25M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 115.92M | 82.26M | 80.70M | 81.99M | 78.45M |
| Operating Income | -27.93M | 4.05M | 5.08M | 5.01M | -5.47M |
| Income Before Tax | -26.27M | 7.89M | 8.28M | 7.89M | -2.49M |
| Income Tax Expenses | -423.00K | -1.71M | 6.01M | -1.03M | 45.00K |
| Earnings from Continuing Operations | -25.85M | 9.59M | 2.27M | 8.92M | -2.53M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -25.85M | 9.59M | 2.27M | 8.92M | -2.53M |
| EBIT | -27.93M | 4.05M | 5.08M | 5.01M | -5.47M |
| EBITDA | 1.84M | 9.82M | 8.62M | 8.36M | -2.13M |
| EPS Basic | -0.90 | 0.34 | 0.08 | 0.32 | -0.09 |
| Normalized Basic EPS | -0.54 | 0.16 | 0.19 | 0.18 | -0.06 |
| EPS Diluted | -0.90 | 0.31 | 0.08 | 0.31 | -0.09 |
| Normalized Diluted EPS | -0.54 | 0.15 | 0.18 | 0.17 | -0.06 |
| Average Basic Shares Outstanding | 28.61M | 28.13M | 27.84M | 27.65M | 27.49M |
| Average Diluted Shares Outstanding | 28.61M | 30.20M | 29.40M | 28.74M | 27.49M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |